HAS1 and atopic eczema: By significantly inhibiting key pruritogenic and inflammatory mediators (TSLP and ET‐1), enhancing the expression of hyaluronic acid synthases (HAS‐1, HAS‐2, HAS‐3), and mitigating oxidative damage through ROS reduction and SOD activation, PCLP addresses the principal pathogenic mechanisms underlying atopic dermatitis and related skin disorders.